Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Mitochondrial carrier homolog 2 is necessary for AML survival

Blood (2020) 136 (1): 81–92.

https://doi.org/10.1182/blood.2019000106

Published: 2020

Includes: Supplemental data

Journal Articles

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

Blood (2019) 134 (Supplement_1): 729.

https://doi.org/10.1182/blood-2019-122784

Published: 2019

Journal Articles

IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

Boaz Nachmias, MD PhD, Veronique Voisin, PhD, Rose Hurren, BSc, Xioaming Wang, Neil Maclean, G. Wei Xu, Ayesh K Seneviratne, BSc, MSc, Changjiang Xu, Gary D Bader, Liran I. Shlush, MD, Aaron D Schimmer, MD PhD

Blood (2019) 134 (Supplement_1): 2530.

https://doi.org/10.1182/blood-2019-122284

Published: 2019

Journal Articles

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML

Sara Mirali, Botham Aaron, Veronique Voisin, PhD, Yihua Qiu, Fieke W Hoff, BSc, Rose Hurren, BSc, Marcela Gronda, MSc, Yulia Jitkova, PhD, G. Wei Xu, Neil MacLean, Xiaoming Wang, Terzah M. Horton, MD PhD, Steven M. Kornblau, MD, Steven M Chan, MD PhD, Gary D Bader, Aaron Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 1335.

https://doi.org/10.1182/blood-2018-99-110869

Published: 2018

Journal Articles

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

Samir H Barghout, BSPharm, MSc, Neil MacLean, G. Wei Xu, Geethu Thomas, PhDMSc,BSc, Zachary Blatman, Rose Hurren, BSc, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 1350.

https://doi.org/10.1182/blood-2018-99-110406

Published: 2018

Journal Articles

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Samir H. Barghout, BSPharm, MSc, Parasvi Patel, BSc (Hons), Xiaoming Wang, G. Wei Xu, Simon Kavanagh, Marcela Gronda, MSc, Rose Hurren, BSc, Danny V. Jeyaraju, PhD, Neil MacLean, Marc Hyer, PhD, Allison Berger, PhD, Tary Traore, Michael Sintchak, Michael Milhollen, Mark D. Minden, MD PhD, Razq Hakem, PhD, Aaron D. Schimmer, MDPhD

Blood (2017) 130 (Supplement 1): 814.

https://doi.org/10.1182/blood.V130.Suppl_1.814.814

Published: 2017

Journal Articles

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

Blood (2017) 130 (Supplement 1): 788.

https://doi.org/10.1182/blood.V130.Suppl_1.788.788

Published: 2017

Journal Articles

Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Dilshad H. Khan, Michael Mullokandov, Yan Wu, Marcela Gronda, MSc, Rose Hurren, BSc, Xiaoming Wang, Neil MacLean, Danny V. Jeyaraju, PhD, G. Wei Xu, Rob C. Laister, PhD, Zachary Blatman, Troy Ketela, Mark D. Minden, MD PhD, Atan Gross, PhD, Aaron D. Schimmer, MDPhD

Blood (2017) 130 (Supplement 1): 299.

https://doi.org/10.1182/blood.V130.Suppl_1.299.299

Published: 2017

Journal Articles

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

G. Wei Xu, MD, PhD, Julia I. Toth, PhD, Sara R. da Silva, BSc, Stacey-Lynn Paiva, BSc, Julie L. Lukkarila, PhD, Rose Hurren, Neil Maclean, BSc, Mahadeo A. Sukhai, PhD, Rabindra N. Bhattacharjee, PhD, Carolyn A. Goard, PhD, Bruno C Medeiros, MD, Patrick T. Gunning, PhD, Sirano Dhe-Paganon, PhD, Matthew D. Petroski, PhD, Aaron Schimmer, PhD, MD

Blood (2013) 122 (21): 2527.

https://doi.org/10.1182/blood.V122.21.2527.2527

Published: 2013

Journal Articles

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

Blood (2010) 115 (11): 2251–2259.

https://doi.org/10.1182/blood-2009-07-231191

Published: 2010

Includes: Supplemental data

Journal Articles

Cyproheptadine displays preclinical activity in myeloma and leukemia

Blood (2008) 112 (3): 760–769.

https://doi.org/10.1182/blood-2008-02-142687

Published: 2008

Includes: Supplemental data

NARROW

Mitochondrial carrier homolog 2 is necessary for AML survival

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Complex and Supercomplex Formation and Is Necessary for AML Viability

IPO11 Is Upregulated in Relapsed AML and Supports Survival of Leukemic Stem Cells

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML

A Genome-Wide CRISPR/Cas9 Knockout Screen Identifies BEND3 As a Determinant of Sensitivity to UBA1 Inhibition in Acute Myeloid Leukemia

TAK-243 Is a Selective UBA1 Inhibitor That Displays Preclinical Activity in Acute Myeloid Leukemia (AML)

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

Cyproheptadine displays preclinical activity in myeloma and leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only